| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | entC3 |
| Uniprot No | P0A0L5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-266aa |
| 氨基酸序列 | ESQPDPMPDDLHKSSEFTGTMGNMKYLYDDHYVSATKVKSVDKFLAHDLIYNISDKKLKNYDKVKTELLNEDLAKKYKDEVVDVYGSNYYVNCYFSSKDNVGKVTGGKTCMYGGITKHEGNHFDNGNLQNVLVRVYENKRNTISFEVQTDKKSVTAQELDIKARNFLINKKNLYEFNSSPYETGYIKFIENNGNTFWYDMMPAPGDKFDQSKYLMMYNDNKTVDSKSVKIEVHLTTKNG |
| 预测分子量 | 43.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于entC3重组蛋白的假设性参考文献示例，供参考：
1. **文献名称**: "Heterologous Expression and Functional Characterization of the entC3-Encoded Isochorismatase in Yersinia pestis"
**作者**: Miller, K.J. et al.
**摘要**: 本研究成功在大肠杆菌中表达了耶尔森菌来源的entC3重组蛋白，证实其编码异分支酸酶活性，参与铁载体合成，并分析了其在不同pH条件下的酶动力学特性。
2. **文献名称**: "Crystallographic Analysis of EntC3: Implications for Substrate Specificity in Siderophore Biosynthesis"
**作者**: García-Sánchez, A. et al.
**摘要**: 通过解析entC3重组蛋白的2.1Å晶体结构，揭示了其底物结合口袋的关键残基，解释了其对异分支酸的选择性催化机制，为抗菌靶点设计提供结构基础。
3. **文献名称**: "Immunogenic Potential of Recombinant EntC3 Protein in a Murine Sepsis Model"
**作者**: Chen, X. & Patel, R.
**摘要**: 评估重组entC3蛋白作为抗毒力疫苗的效果，证明其免疫小鼠后能显著降低沙门氏菌感染的细菌载量，并减少铁载体介导的铁摄取能力。
4. **文献名称**: "Metabolic Engineering of entC3 for Enhanced Enterobactin Production in Industrial E. coli Strains"
**作者**: Schmidt, F. et al.
**摘要**: 通过优化entC3重组蛋白的表达水平，结合发酵调控，使工程菌株肠杆菌素产量提升3.7倍，为微生物铁载体规模化生产提供新策略。
*注：上述文献为模拟示例，实际研究中请通过学术数据库检索具体文献。*
EntC3 recombinant protein is a genetically engineered derivative of the Staphylococcus aureus enterotoxin C3 (SEC3), a member of the staphylococcal enterotoxin (SE) family. SEs are superantigenic exotoxins notorious for causing food poisoning and toxic shock syndrome by hyperactivating the host immune system. Unlike conventional antigens, SEC3 binds directly to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells and specific T-cell receptor (TCR) Vβ regions, triggering uncontrolled proliferation of T lymphocytes. This excessive immune response leads to cytokine storms, tissue damage, and systemic inflammation.
The entC3 gene, encoding SEC3. has been cloned and expressed in heterologous systems like Escherichia coli to produce recombinant SEC3. This recombinant form retains the superantigenic properties of native SEC3 but is often generated in purified, endotoxin-free formats for research and diagnostic applications. Its production enables controlled studies on SE-mediated pathogenesis, immune evasion mechanisms, and host-pathogen interactions.
Recombinant EntC3 is widely utilized to investigate superantigen-driven diseases, develop toxin-neutralizing antibodies, and screen potential therapeutic inhibitors. It also serves as a critical tool for understanding T-cell activation pathways and MHC II-TCR crosslinking dynamics. Recent studies explore its role in cancer immunotherapy due to its ability to nonspecifically activate T cells. However, safety concerns necessitate rigorous purification and containment protocols.
The development of recombinant EntC3 has accelerated structural studies, revealing its conserved β-barrel fold and key residues involved in MHC/TCR binding. This knowledge aids in designing attenuated variants for vaccines or targeted therapies. As a standardized reagent, recombinant EntC3 supports food safety testing, epidemiological surveillance of S. aureus strains, and evaluation of decontamination strategies targeting heat-stable SEs. Its engineered production underscores the balance between leveraging pathogen-derived molecules for biomedical innovation and mitigating their inherent risks.
×
